COMPOSITIONS AND METHODS OF TREATMENT USING MODULATORS OF MOTONUERON DISEASES
    2.
    发明公开
    COMPOSITIONS AND METHODS OF TREATMENT USING MODULATORS OF MOTONUERON DISEASES 审中-公开
    组合物和方法疾病与欧元MOTO调节剂治疗

    公开(公告)号:EP1978962A2

    公开(公告)日:2008-10-15

    申请号:EP07717779.8

    申请日:2007-01-05

    申请人: Kinemed, Inc.

    摘要: The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules in neurons); a method for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease; the discovery of drug agents that modulate neuronal microtubule dynamics in living subjects with motoneuron diseases; the discovery that administration of such agents, alone or in combinations, can provide marked neuroprotective therapy for living subjects with motoneuron diseases including delay in symptoms and prolongation of survival; and the discovery that monitoring of neuronal microtubule dynamics in subjects with motoneuron diseases, in response to therapeutic interventions, allows diagnostic monitoring for optimization of therapeutic regimen and strategy for individual subjects or for drug trials.

    BIOMARKERS
    4.
    发明公开
    BIOMARKERS 审中-公开
    生物标志物

    公开(公告)号:EP2972329A2

    公开(公告)日:2016-01-20

    申请号:EP14730243.4

    申请日:2014-03-17

    IPC分类号: G01N33/50 G01N33/68

    摘要: The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules and microtubule-mediated axonal transport of cargo molecules in neurons), with or without dementia, and in dementia; methods for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease, with or without dementia, and in dementia; the discovery of drug agents that modulate neuronal microtubule dynamics in living subjects with motoneuron diseases; the discovery that administration of such agents, alone or in combinations, can improve MT-mediated transport of cargo molecules along and through axons; the discovery that such modulation of altered microtubule dynamics and improvement in MT -transport of molecules along axons can provide marked neuroprotective therapy for living subjects with motoneuron diseases, including delay in symptoms and prolongation of survival; and the discovery that monitoring of microtubule-mediated axonal transport of cargo molecules in response to therapeutic interventions in subjects with motoneuron diseases, with or without dementia,and in dementia allows diagnostic monitoring, to optimize therapeutic regimens and treatment strategies in individual subjects or in drug trials.

    摘要翻译: 本文公开的发明描述了运动神经元疾病(改变神经元中的货物分子的微管和微管介导的轴突运输的动力学),伴或不伴痴呆以及痴呆的新型治疗靶点; 用于测定具有确定的,初期的或潜在的运动神经元疾病,伴或不伴痴呆以及痴呆的受试者中该治疗靶活性状态的方法; 发现调节运动神经元疾病活体患者的神经元微管动力学的药物; 发现单独或联合给予这些药物可以改善MT-介导的货物分子沿着和穿过轴突的运输; 发现这种对微管动力学改变的调节和MT-轴突分子运输的改善可以为运动神经元疾病的活体患者提供显着的神经保护性治疗,包括延缓症状和延长生存期; 以及在运动神经元疾病患者,伴或不伴痴呆患者以及痴呆患者进行治疗性干预措施时,监测微管介导的货物分子的轴突转运可以进行诊断监测,以优化个体受试者或药物治疗方案和治疗策略 试验。

    METHOD FOR REPLACING BIOMARKERS OF PROTEIN KINETICS FROM TISSUE SAMPLES BY BIOMARKERS OF PROTEIN KINETICS FROM BODY FLUIDS AFTER ISOTOPIC LABELING IN VIVO
    7.
    发明公开
    METHOD FOR REPLACING BIOMARKERS OF PROTEIN KINETICS FROM TISSUE SAMPLES BY BIOMARKERS OF PROTEIN KINETICS FROM BODY FLUIDS AFTER ISOTOPIC LABELING IN VIVO 审中-公开
    方法更换的生物标志物蛋白动力学组织样品BY生物标志物蛋白动力学体液同位素后体内MARK

    公开(公告)号:EP2972389A1

    公开(公告)日:2016-01-20

    申请号:EP14722040.4

    申请日:2014-03-14

    IPC分类号: G01N33/68

    摘要: Provided herein are method for measuring the rate of synthesis, breakdown, transport, or other kinetic parameters of a protein in a tissue of medical interest, without requiring physical sampling of the tissue, by a measurement of the protein in a body fluid. Methods may include selecting one or more target proteins in a tissue; administering an isotope-labeled molecule to a subject for a period of time sufficient for said isotope-labeled molecule to enter into and label the one or more target proteins to produce one or more isotope-labeled target proteins; collecting a volume of a body fluid, wherein the volume comprises one or more isotope-labeled target proteins that escaped or were released from the tissue; enriching or isolating the one or more isotope-labeled target proteins from the volume; performing a mass spectrometric measurement of the isotopic content, rate of incorporation, and/or pattern or rate of change in isotopic content and/or pattern of isotope labeling of the one or more enriched or isolated isotope-labeled target proteins; and calculating at least one kinetic parameter of the one or more enriched or isolated isotope-labeled target proteins, where the kinetic parameter of the one or more isotope-labeled target proteins from the volume of a body fluid reflects the corresponding kinetic parameter of the one or more target proteins in the tissue; and inferring the at least one kinetic parameter of the one or more target proteins in the tissue based on the corresponding at least one kinetic parameter of the one or more target proteins in the body fluid.

    KINETIC BIOMARKER FOR QUANTIFICATION OF LYMPHOPROLIFERATION, CLONAL EXPANSION, RECRUITMENT AND TRAFFICKING IN LYMPHOID TISSUES AND OF THE IN VIVO ACTIONS OF ANTIGENS AND MODULATING AGENTS THEREON
    9.
    发明公开
    KINETIC BIOMARKER FOR QUANTIFICATION OF LYMPHOPROLIFERATION, CLONAL EXPANSION, RECRUITMENT AND TRAFFICKING IN LYMPHOID TISSUES AND OF THE IN VIVO ACTIONS OF ANTIGENS AND MODULATING AGENTS THEREON 审中-公开
    KINETIC生物标志物的定量淋巴组织增生的,克隆扩增,招聘和贩卖淋巴和抗原,并应MODULATIONSAGENTIEN的体内影响

    公开(公告)号:EP1934600A2

    公开(公告)日:2008-06-25

    申请号:EP06814223.1

    申请日:2006-09-06

    申请人: Kinemed, Inc.

    IPC分类号: G01N33/50

    CPC分类号: G01N33/5047 G01N33/5088

    摘要: The methods of the present invention allow for the measurement of proliferation, clonal expansion trafficking and/or recruitment of lymphocytes into lymphoid tissue in an in vivo setting. Proliferation, clonal expansion, recruitment and/or trafficking of lymphocytes are measured by using stable isotopes to label newly synthesized DNA, isolating the newly-labeled DNA, and quantifying enrichment of the isolated DNA with mass spectrometry or other appropriate techniques. Such methods are useful in screening candidate drugs for stimulatory or inhibitory effects on proliferation, clonal expansion, recruitment and/or trafficking of lymphocytes. The methods also allow for the discovery of therapeutic agents in disorders of immune regulation such as HIV infection and for optimizing vaccine efficacy.